DaVita

Valuation Analysis

About the Company

DaVita en bref

DaVita (DVA) is currently trading at 208,65 € with a market capitalization of 13,4 Md €. The trailing P/E ratio stands at 23.15x, with a forward P/E of 13.94x. The 52-week range spans from 87,77 € to 212,47 €; the current price is 1.8% below the yearly high. Year-over-year revenue growth stands at +6.0%. The net profit margin stands at 5.65%.

💰 Dividende

DaVita currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent DaVita (DVA) au consensus : Conserver. L'objectif de cours moyen est de 181,25 €, soit un potentiel de -13.13% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 126,01 € à 234,64 €.

DaVita : la thèse d'investissement en détail

DaVita (DVA) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 43.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Return on equity of 80.98% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

The debt-to-equity ratio of 1261.33% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 13.7% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

With a PEG ratio of 0.75, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 13.94x is meaningfully below the trailing 23.15x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 96.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (13.7%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy DaVita?

Compare top-rated brokers — low fees, trusted providers, fully regulated.